India API Import Dependency: China Pharmaceutical Supply Chain

What percentage of its Active Pharmaceutical Ingredients (APIs) does India import primarily from China?

Correct Answer: 65–70%

India imports 65–70% of its Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) primarily from China. This represents a classic midstream vulnerability in India's pharmaceutical supply chain. The Indian pharma industry scaled up rapidly by sourcing cheap Chinese intermediates rather than investing in costly domestic chemical ecosystems. India is globally competitive in downstream activities like generic drug formulation, but critically deficient in upstream raw materials and midstream intermediate components. A sudden supply chain decoupling, trade war, or geopolitical standoff with China could bring India's multi-billion-dollar drug manufacturing industry to a grinding halt within weeks, severely impacting global medicine supply as India is the world's largest supplier of generic medicines.

India's Pharmaceutical Supply Chain — Structural Position

• Downstream strength: Generic drug formulation, final manufacturing — globally competitive
• Midstream weakness: APIs and KSMs — 65–70% imported from China
• Upstream weakness: Core chemical building blocks — largely absent domestically
• PLI Scheme: Government launched PLI for bulk drugs to reduce API import dependency
• Risk: Geopolitical standoff with China could halt drug production within weeks

Why Other Options Are Wrong

• 30–40% — This significantly underestimates India's API import dependency from China; the actual figure is 65–70%.
• 45–55% — Still too low; does not correctly reflect the midstream vulnerability cited in official assessments.
• 80–85% — This overestimates the API import share; 80–85% is India's crude oil import dependency, not API dependency.

India अपने Active Pharmaceutical Ingredients (APIs) का कितना Percentage मुख्य रूप से China से Import करता है?

Correct Answer: 65–70%

India अपने Active Pharmaceutical Ingredients (APIs) और Key Starting Materials (KSMs) का 65–70% मुख्य रूप से China से Import करता है। यह India की Pharmaceutical Supply Chain में एक क्लासिक Midstream Vulnerability (मध्यवर्ती आपूर्ति कमज़ोरी) है। Indian Pharma Industry ने Costly Domestic Chemical Ecosystems बनाने की बजाय सस्ते Chinese Intermediates से Scaling Up किया। India Downstream Activities जैसे Generic Drug Formulation में Globally Competitive है, लेकिन Upstream Raw Materials और Midstream Intermediate Components में critically कमज़ोर है। China के साथ Geopolitical Standoff (भू-राजनीतिक टकराव) की स्थिति में India की Multi-Billion Dollar Drug Manufacturing Industry हफ्तों में ठप हो सकती है।

India की Pharmaceutical Supply Chain — Structural Position

• Downstream Strength (निचली धारा की मजबूती): Generic Drug Formulation — Globally Competitive
• Midstream Weakness (मध्यवर्ती कमज़ोरी): APIs और KSMs — 65–70% China से Imported
• Upstream Weakness (ऊपरी धारा की कमज़ोरी): Core Chemical Building Blocks — Domestic Level पर लगभग अनुपस्थित
• PLI Scheme: सरकार ने API Import Dependency कम करने के लिए Bulk Drugs के लिए PLI Launch किया
• Risk (जोखिम): China के साथ Geopolitical Standoff से हफ्तों में Drug Production रुक सकती है

Other Options क्यों गलत हैं

• 30–40% — यह China से India की API Import Dependency को काफी कम आंकता है; सही आंकड़ा 65–70% है।
• 45–55% — यह अभी भी बहुत कम है; Official Assessments में उद्धृत Midstream Vulnerability को सही तरह Reflect नहीं करता।
• 80–85% — यह API Import Share को Overestimate करता है; 80–85% India की Crude Oil Import Dependency है, API Dependency नहीं।